Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Verastem, Inc. (VSTM)
USD5.37
-0.16 (-2.89%)
US NASDAQ Healthcare Biotechnology
Address
117 Kendrick Street 2494
Needham, MA, US
Needham, MA, US
CEO
Daniel W. Paterson
Website
verastem.com
IPO
2012-01-27
CIK 1526119 ISIN US92337C2035
Also trades on
Frankfurt Stock Exchange · 2VSA.F (EUR)
London Stock Exchange · 0LOV.L (USD)
NASDAQ Global Market · VSTM (USD)
Description
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
- Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.37
-0.16 (-2.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.29
Float Shares
52.98M
Free Float %
76.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20% | -18.39% | -8.10% | -16.44% | -42.66% | -36.79% | -33.06% | +1.67% | -85.48% | -70.74% | -96.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
5.37
Low
18.00
+235.2%
Consensus
18.25
+239.9%
Median
18.00
+235.2%
High
19.00
+253.8%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
18.50
+244.5%
|
| Last Year | 6 |
15.50
+188.6%
|
| All Time | 11 |
12.91
+140.4%
|
Quality scores
Altman Z-Score
-8.11
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+209.1% ★
-
EPS growth Biotechnology: +29.7%+17.5% Q1'26: +61.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-469.9% Q1'26: -279.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-550.3% Q1'26: -240.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +1,244.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+94.1% Q1'26: +83.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.45× Q1'26: -0.48× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 3 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.72M
est: 28.45M (-6.1%)
|
17.46M
est: 16.41M (+6.3%)
|
88.52M
est: 54.61M (+62.1%)
|
2.05M
est: 1.47M (+39.7%)
|
2.60M
est: 2.66M (-2.6%)
|
—
est: 10.00M (-100.0%)
|
10.00M
est: 7.70M (+29.9%)
|
30.91M
est: 30.25M (+2.2%)
|
106.11M
103.48M – 110.60M
+250.8% YoY
|
190.12M
176.07M – 224.23M
+79.2% YoY
|
291.88M
286.99M – 296.76M
+53.5% YoY
|
443.43M
410.67M – 522.99M
+51.9% YoY
|
601.50M
557.06M – 709.41M
+35.6% YoY
|
| EBITDA |
-65.21M
est: -14.62M (-345.9%)
|
-126.42M
est: -8.44M (-1,398.2%)
|
-50.48M
est: -28.07M (-79.8%)
|
-61.16M
est: -755.3K (-7,996.6%)
|
-71.56M
est: -1.37M (-5,125.2%)
|
-83.17M
est: -6.00M (-1,286.1%)
|
-125.86M
est: -4.62M (-2,624.3%)
|
-170.13M
est: -18.15M (-837.4%)
|
-63.67M
-66.36M – -62.09M
-250.8% YoY
|
-114.07M
-134.54M – -105.64M
-79.2% YoY
|
-175.13M
-178.06M – -172.19M
-53.5% YoY
|
-266.06M
-313.79M – -246.40M
-51.9% YoY
|
-360.90M
-425.65M – -334.23M
-35.6% YoY
|
| EBIT |
-66.62M
est: -14.70M (-353.1%)
|
-128.60M
est: -8.48M (-1,415.7%)
|
-51.74M
est: -28.23M (-83.3%)
|
-61.23M
est: -759.5K (-7,961.6%)
|
-71.68M
est: -1.38M (-5,105.1%)
|
-83.23M
est: -6.00M (-1,287.1%)
|
-125.89M
est: -4.62M (-2,624.9%)
|
-170.13M
est: -18.15M (-837.4%)
|
-63.67M
-66.36M – -62.09M
-250.8% YoY
|
-114.07M
-134.54M – -105.64M
-79.2% YoY
|
-175.13M
-178.06M – -172.19M
-53.5% YoY
|
-266.06M
-313.79M – -246.40M
-51.9% YoY
|
-360.90M
-425.65M – -334.23M
-35.6% YoY
|
| Net Income |
-72.43M
est: -663.55M (+89.1%)
|
-149.21M
est: -849.61M (+82.4%)
|
-67.73M
est: -173.57M (+61.0%)
|
-71.20M
est: -169.99M (+58.1%)
|
-73.81M
est: -166.10M (+55.6%)
|
-87.37M
est: -246.75M (+64.6%)
|
-130.64M
est: -209.05M (+37.5%)
|
-209.47M
est: -222.48M (+5.8%)
|
-109.99M
-123.42M – -96.56M
+50.6% YoY
|
-75.02M
-86.57M – -63.46M
+31.8% YoY
|
-55.41M
-81.86M – -5.01M
+26.1% YoY
|
5.54M
5.01M – 6.84M
+110.0% YoY
|
53.83M
48.66M – 66.38M
+870.8% YoY
|
| SGA |
77.27M
est: 156.10M (-50.5%)
|
101.21M
est: 90.07M (+12.4%)
|
62.76M
est: 299.66M (-79.1%)
|
24.12M
est: 8.06M (+199.1%)
|
24.98M
est: 14.62M (+70.8%)
|
30.73M
est: 58.71M (-47.7%)
|
43.62M
est: 45.20M (-3.5%)
|
81.15M
est: 177.59M (-54.3%)
|
622.97M
607.51M – 649.30M
+250.8% YoY
|
1.12B
1.03B – 1.32B
+79.2% YoY
|
1.71B
1.68B – 1.74B
+53.5% YoY
|
2.60B
2.41B – 3.07B
+51.9% YoY
|
3.53B
3.27B – 4.16B
+35.6% YoY
|
| EPS |
-12.54
est: -18.58 (+32.5%)
|
-27.22
est: -23.79 (-14.4%)
|
-5.28
est: -4.86 (-8.6%)
|
-4.92
est: -4.76 (-3.4%)
|
-4.57
est: -4.71 (+3.0%)
|
-3.96
est: -3.33 (-18.9%)
|
-3.66
est: -3.03 (-20.7%)
|
-3.02
est: -3.21 (+5.9%)
|
-1.58
-1.78 – -1.39
+50.8% YoY
|
-1.01
-1.25 – -0.92
+35.8% YoY
|
-0.54
-1.18 – -0.07
+46.9% YoY
|
0.08
0.07 – 0.10
+114.9% YoY
|
0.78
0.70 – 0.96
+870.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-23 | BTIG | Buy | Buy | Maintain |
| 2026-04-20 | BTIG | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-147.73M
OE per share TTM
-1.79
Owner's Yield
-26.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
9.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
23
Total invested
20.90M
Insider transactions (90d)
1
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Advisors LLC | 16.50M | 7.90% | — | 16.50M | — | — | IA | Delaware | 2023-02-14 | ↗ |
| 2 | OrbiMed Capital GP IX LLC | 12.35M | 5.90% | — | 12.35M | — | — | OO | Delaware | 2023-02-14 | ↗ |
| 3 | Alyeska Fund GP, LLC | 2.86M | 7.11% | — | 2.86M | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 4 | Alyeska Investment Group, L.P. | 2.86M | 7.11% | — | 2.86M | — | — | IA | Delaware | 2024-11-14 | ↗ |
| 5 | Anand Parekh | 2.86M | 7.11% | — | 2.86M | — | — | IN | Delaware | 2024-11-14 | ↗ |
| 6 | Jon M. Plexico | 2.67M | 11.00% | — | 2.67M | — | 2.67M | HC, IN | U.S.A. | 2024-07-29 | ↗ |
| 7 | Stonepine Capital Management, LLC | 2.67M | 11.00% | — | 2.67M | — | 2.67M | IA, OO | Delaware | 2024-07-29 | ↗ |
| 8 | Stonepine Capital, L.P. | 2.67M | 11.00% | — | 2.67M | — | 2.67M | PN | Delaware | 2024-07-29 | ↗ |
| 9 | Stonepine GP, LLC | 2.67M | 11.00% | — | 2.67M | — | 2.67M | OO | Delaware | 2024-07-29 | ↗ |
| 10 | Timothy P. Lynch | 2.67M | 11.00% | — | 2.67M | — | 2.67M | HC, IN | U.S.A. | 2024-07-29 | ↗ |
| 11 | (1) BlackRock, Inc. | 2.23M | 5.60% | 2.23M | — | 2.23M | — | HC | Delaware | 2024-11-08 | ↗ |
| 12 | Company, L.P. | 1.54M | 6.10% | — | 1.54M | — | — | PN | Delaware | 2023-06-23 | ↗ |
| 13 | Deerfield Mgmt, L.P. | 1.54M | 6.10% | — | 1.54M | — | — | PN | Delaware | 2023-06-23 | ↗ |
| 14 | Deerfield Partners, L.P. | 1.54M | 6.10% | — | 1.54M | — | — | PN | Delaware | 2023-06-23 | ↗ |
| 15 | James E. Flynn | 1.54M | 6.10% | — | 1.54M | — | — | IN | Delaware | 2023-06-23 | ↗ |
| 16 | Viking Global Investors LP | 1.32M | 7.90% | — | 1.32M | — | 1.32M | — | Delaware | 2023-06-05 | ↗ |
| 17 | Adage Capital Management, L.P. | 1.30M | 5.15% | — | 1.30M | — | — | IA, PN | Delaware | 2023-08-31 | ↗ |
| 18 | Adage Capital Partners GP, L.L.C. | 1.30M | 5.15% | — | 1.30M | — | — | OO | Delaware | 2023-08-31 | ↗ |
| 19 | Adage Capital Partners, L.P. | 1.30M | 5.15% | — | 1.30M | — | — | PN | Delaware | 2023-08-31 | ↗ |
| 20 | Phillip Gross | 1.30M | 5.15% | — | 1.30M | — | — | IN | Delaware | 2023-08-31 | ↗ |
| 21 | Robert Atchinson | 1.30M | 5.15% | — | 1.30M | — | — | IN | Delaware | 2023-08-31 | ↗ |
| 22 | Group, LLC | 1.30M | 5.10% | — | 1.30M | — | 1.30M | OO | Delaware | 2023-07-27 | ↗ |
| 23 | LLC | 1.30M | 5.10% | — | 1.30M | — | 1.30M | OO | Delaware | 2023-07-27 | ↗ |
| 24 | Levy | 1.30M | 5.10% | — | 1.30M | — | 1.30M | IN | Delaware | 2023-07-27 | ↗ |
| 25 | Master Fund, L.P. | 1.30M | 5.10% | — | 1.30M | — | 1.30M | FI | Delaware | 2023-07-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
23
-126 vs prev Q
New positions
5
Closed positions
124
Increased
14
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 390.5K +390.5K (+100.0%) | 3.01B +3.0B (+100.0%) | 0.53% +0.534 pp | 0.02% +0.023 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 2 | RTW INVESTMENTS, LP | 6.58M +1.2M (+21.2%) | 50.77M +2.9M (+6.0%) | 8.99% +0.785 pp | 0.51% -0.082 pp | USD6.82 +13.2% | 4 qtrs — |
| 3 | DEEP TRACK CAPITAL, LP | 5.74M +5.7M (+100.0%) | 44.32M +44.3M (+100.0%) | 7.85% +7.847 pp | 0.79% +0.790 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 4 | BLACKROCK, INC. | 4.75M +1.0M (+27.9%) | 36.69M +3.9M (+11.8%) | 6.50% +0.877 pp | 0.00% +0.000 pp | USD5.41 +42.7% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 4.15M +673.7K (+19.4%) | 32.06M +1.3M (+4.4%) | 5.68% +0.417 pp | 0.00% +0.000 pp | USD5.69 +35.7% | 11 qtrs — |
| 6 | POLAR CAPITAL HOLDINGS PLC | 3.93M +2.9M (+270.7%) | 30.30M +21.0M (+224.1%) | 5.37% +3.765 pp | 0.12% +0.072 pp | USD6.83 +13.0% | 3 qtrs — |
| 7 | ARMISTICE CAPITAL, LLC | 3.54M +1.4M (+68.7%) | 27.30M +8.8M (+47.5%) | 4.83% +1.665 pp | 0.32% +0.050 pp | USD5.60 +37.9% | 3 qtrs — |
| 8 | STATE STREET CORP | 3.22M +990.7K (+44.5%) | 24.85M +5.2M (+26.3%) | 4.40% +1.031 pp | 0.00% +0.000 pp | USD5.39 +43.2% | 11 qtrs — |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 3.20M -951.0K (-22.9%) | 24.67M -11.9M (-32.6%) | 4.37% -1.901 pp | 0.03% -0.015 pp | USD5.32 +45.1% | 5 qtrs — |
| 10 | FORESITE CAPITAL MANAGEMENT VI LLC | 3.14M +520.0K (+19.9%) | 24.20M +1.1M (+4.8%) | 4.29% +0.332 pp | 7.32% -1.605 pp | USD6.74 +14.5% | 3 qtrs — |
| 11 | STONEPINE CAPITAL MANAGEMENT, LLC | 2.73M +62.0K (+2.3%) | 21.09M -2.5M (-10.5%) | 3.73% -0.302 pp | 15.40% -3.768 pp | USD6.21 +24.3% | 6 qtrs — |
| 12 | CITADEL ADVISORS LLC | 2.35M +2.2M (+1,173.2%) | 18.17M +16.5M (+1,013.2%) | 3.22% +2.938 pp | 0.00% +0.003 pp | USD7.81 -1.2% | 2 qtrs — |
| 13 | FARALLON CAPITAL MANAGEMENT LLC | 2.00M +2.0M (+100.0%) | 15.44M +15.4M (+100.0%) | 2.73% +2.734 pp | 0.07% +0.073 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 14 | MORGAN STANLEY | 1.87M +292.1K (+18.5%) | 14.45M +501.6K (+3.6%) | 2.56% +0.170 pp | 0.00% +0.000 pp | USD6.58 +17.3% | 11 qtrs — |
| 15 | ROSALIND ADVISORS, INC. | 1.79M -141.1K (-7.3%) | 13.81M -3.2M (-19.0%) | 2.44% -0.473 pp | 4.85% -0.971 pp | USD5.74 +34.5% | 5 qtrs — |
| 16 | LOGOS GLOBAL MANAGEMENT LP | 1.70M -2.4M (-58.0%) | 13.12M -22.6M (-63.3%) | 2.32% -3.799 pp | 0.79% -2.412 pp | USD7.67 +0.7% | 3 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 1.50M +1.2M (+504.4%) | 11.54M +9.4M (+428.4%) | 2.04% +1.670 pp | 0.00% +0.001 pp | USD7.29 +5.9% | 11 qtrs — |
| 18 | ACORN CAPITAL ADVISORS, LLC | 1.47M +689.7K (+88.5%) | 11.34M +4.5M (+64.8%) | 2.01% +0.830 pp | 3.84% +0.349 pp | USD6.37 +21.2% | 5 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 1.39M +148.2K (+11.9%) | 10.76M -236.7K (-2.2%) | 1.90% +0.022 pp | 0.00% +0.000 pp | USD4.93 +56.6% | 11 qtrs — |
| 20 | VIVO CAPITAL, LLC | 1.11M -1.5M (-58.2%) | 8.54M -14.8M (-63.4%) | 1.51% -2.486 pp | 0.55% -1.327 pp | USD8.02 -3.7% | 11 qtrs — |
| 21 | TANG CAPITAL MANAGEMENT LLC | 1.07M +280.0K (+35.5%) | 8.26M +1.3M (+18.4%) | 1.46% +0.268 pp | 0.41% +0.140 pp | USD8.19 -5.7% | 11 qtrs — |
| 22 | POINT72 ASSET MANAGEMENT, L.P. | 995.0K -2.9M (-74.4%) | 7.68M -26.6M (-77.6%) | 1.36% -4.505 pp | 0.01% -0.049 pp | USD8.83 -12.6% | 2 qtrs — |
| 23 | J. GOLDMAN & CO LP | 947.3K +533.4K (+128.9%) | 7.31M +3.7M (+100.1%) | 1.29% +0.669 pp | 0.19% +0.101 pp | USD6.22 +24.1% | 4 qtrs — |
| 24 | FRANKLIN RESOURCES INC | 926.0K +926.0K (+100.0%) | 7.15M +7.1M (+100.0%) | 1.27% +1.266 pp | 0.00% +0.002 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 25 | JEFFERIES FINANCIAL GROUP INC. | 557.0K -33.2K (-5.6%) | 4.30M -911.2K (-17.5%) | 0.76% -0.131 pp | 0.02% -0.003 pp | USD6.54 +18.0% | 4 qtrs — |
| 26 | MILLENNIUM MANAGEMENT LLC | 555.1K -604.5K (-52.1%) | 4.29M -6.0M (-58.1%) | 0.76% -0.994 pp | 0.00% -0.003 pp | USD8.69 -11.2% | 9 qtrs — |
| 27 | UBS GROUP AG | 501.5K +217.1K (+76.3%) | 3.87M +1.4M (+54.2%) | 0.69% +0.256 pp | 0.00% +0.000 pp | USD5.96 +29.5% | 11 qtrs — |
| 28 | TWO SIGMA INVESTMENTS, LP | 476.9K +52.6K (+12.4%) | 3.68M -64.5K (-1.7%) | 0.65% +0.011 pp | 0.01% 0.000 pp | USD4.52 +70.8% | 11 qtrs — |
| 29 | NANTAHALA CAPITAL MANAGEMENT, LLC | 462.1K -830.8K (-64.3%) | 3.57M -7.8M (-68.7%) | 0.63% -1.323 pp | 0.12% -0.279 pp | USD3.28 +135.4% | 7 qtrs — |
| 30 | TORONTO DOMINION BANK | 460.4K +— (+0.0%) | 3.55M -511.1K (-12.6%) | 0.63% -0.067 pp | 0.01% -0.001 pp | USD8.83 -12.6% | 2 qtrs — |
| 31 | EXOME ASSET MANAGEMENT LLC | 401.7K +401.7K (+100.0%) | 3.10M +3.1M (+100.0%) | 0.55% +0.549 pp | 1.48% +1.483 pp | USD7.72 +0.0% | 3 qtrs — |
| 32 | TWO SIGMA ADVISERS, LP | 399.0K +311.9K (+358.1%) | 3.08M +2.3M (+300.5%) | 0.55% +0.414 pp | 0.01% +0.004 pp | USD6.88 +12.2% | 6 qtrs — |
| 33 | FMR LLC | 398.5K +78.3K (+24.4%) | 3.08M +248.9K (+8.8%) | 0.54% +0.061 pp | 0.00% +0.000 pp | USD6.41 +20.4% | 11 qtrs — |
| 34 | NORTHERN TRUST CORP | 393.1K +15.8K (+4.2%) | 3.03M -296.8K (-8.9%) | 0.54% -0.033 pp | 0.00% +0.000 pp | USD4.38 +76.3% | 11 qtrs — |
| 35 | SG AMERICAS SECURITIES, LLC | 390.3K +379.0K (+3,333.8%) | 3.01M +2.9M (+2,913.0%) | 0.53% +0.516 pp | 0.00% +0.004 pp | USD7.62 +1.3% | 6 qtrs — |
| 36 | CITIGROUP INC | 364.4K +362.4K (+17,986.2%) | 2.81M +2.8M (+15,712.1%) | 0.50% +0.495 pp | 0.00% +0.001 pp | USD7.70 +0.3% | 10 qtrs — |
| 37 | Y-INTERCEPT (HONG KONG) LTD | 364.3K +350.0K (+2,447.8%) | 2.81M +2.7M (+2,127.5%) | 0.50% +0.476 pp | 0.06% +0.060 pp | USD7.58 +1.8% | 3 qtrs — |
| 38 | SPHERA FUNDS MANAGEMENT LTD. | 343.7K +265.4K (+338.9%) | 2.65M +2.0M (+283.7%) | 0.47% +0.351 pp | 0.51% +0.367 pp | USD6.91 +11.7% | 3 qtrs — |
| 39 | D. E. SHAW & CO., INC. | 338.9K -23.7K (-6.5%) | 2.62M -585.8K (-18.3%) | 0.46% -0.085 pp | 0.00% 0.000 pp | USD8.83 -12.6% | 2 qtrs — |
| 40 | BANK OF AMERICA CORP /DE/ | 316.9K +167.1K (+111.5%) | 2.45M +1.1M (+85.0%) | 0.43% +0.207 pp | 0.00% +0.000 pp | USD6.05 +27.6% | 11 qtrs — |
| 41 | SQUAREPOINT OPS LLC | 275.9K +131.6K (+91.1%) | 2.13M +855.4K (+67.1%) | 0.38% +0.159 pp | 0.00% +0.001 pp | USD5.87 +31.5% | 5 qtrs — |
| 42 | POLYMER CAPITAL MANAGEMENT (HK) LTD | 266.8K -43.0K (-13.9%) | 2.06M -675.6K (-24.7%) | 0.36% -0.104 pp | 0.29% -0.084 pp | USD8.83 -12.6% | 2 qtrs — |
| 43 | QUBE RESEARCH & TECHNOLOGIES LTD | 254.9K +254.9K (+100.0%) | 1.97M +2.0M (+100.0%) | 0.35% +0.348 pp | 0.00% +0.002 pp | USD7.72 +0.0% | 3 qtrs — |
| 44 | PANAGORA ASSET MANAGEMENT INC | 244.1K +17.8K (+7.9%) | 1.88M -113.5K (-5.7%) | 0.33% -0.008 pp | 0.01% -0.001 pp | USD6.21 +24.3% | 3 qtrs — |
| 45 | TORRAY INVESTMENT PARTNERS LLC | 216.4K +216.4K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.30% +0.296 pp | 0.24% +0.239 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 46 | IKARIAN CAPITAL, LLC | 213.9K +213.9K (+100.0%) | 1.65M +1.7M (+100.0%) | 0.29% +0.292 pp | 0.13% +0.129 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 47 | BARCLAYS PLC | 201.8K +146.1K (+262.3%) | 1.56M +1.4M (+835.5%) | 0.28% +0.192 pp | 0.00% +0.000 pp | USD6.75 +14.4% | 11 qtrs — |
| 48 | RAYMOND JAMES FINANCIAL INC | 199.3K +78.0 (+0.0%) | 1.54M -220.6K (-12.5%) | 0.27% -0.029 pp | 0.00% 0.000 pp | USD8.78 -12.1% | 3 qtrs — |
| 49 | NUVEEN, LLC | 188.7K +7.5K (+4.1%) | 1.46M -143.6K (-9.0%) | 0.26% -0.016 pp | 0.00% +0.000 pp | USD4.53 +70.4% | 4 qtrs — |
| 50 | HENNION & WALSH ASSET MANAGEMENT, INC. | 174.4K +174.4K (+100.0%) | 1.35M +1.3M (+100.0%) | 0.24% +0.238 pp | 0.05% +0.047 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 51 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 161.2K +17.8K (+12.4%) | 1.24M -22.0K (-1.7%) | 0.22% +0.004 pp | 0.00% +0.000 pp | USD4.61 +67.5% | 8 qtrs — |
| 52 | TREXQUANT INVESTMENT LP | 154.8K -36.8K (-19.2%) | 1.19M -496.5K (-29.4%) | 0.21% -0.078 pp | 0.01% -0.007 pp | USD8.83 -12.6% | 2 qtrs — |
| 53 | BIRCHVIEW CAPITAL, LP | 150.0K +150.0K (+100.0%) | 1.16M +1.2M (+100.0%) | 0.21% +0.205 pp | 0.68% +0.678 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 54 | WELLINGTON MANAGEMENT GROUP LLP | 145.5K -9.5K (-6.1%) | 1.12M -245.4K (-17.9%) | 0.20% -0.036 pp | 0.00% +0.000 pp | USD5.96 +29.5% | 4 qtrs — |
| 55 | ACUTA CAPITAL PARTNERS, LLC | 143.4K +— (+0.0%) | 1.11M -159.2K (-12.6%) | 0.20% -0.021 pp | 0.75% -0.557 pp | USD6.03 +28.0% | 4 qtrs — |
| 56 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 143.3K -54.4K (-27.5%) | 1.11M -639.2K (-36.6%) | 0.20% -0.103 pp | 0.00% 0.000 pp | USD6.18 +24.9% | 11 qtrs — |
| 57 | XTX TOPCO LTD | 131.1K +82.2K (+168.1%) | 1.01M +580.4K (+134.4%) | 0.18% +0.105 pp | 0.03% +0.004 pp | USD6.39 +20.8% | 6 qtrs — |
| 58 | RAFFERTY ASSET MANAGEMENT, LLC | 129.3K +37.5K (+40.8%) | 998.5K +187.4K (+23.1%) | 0.18% +0.038 pp | 0.00% +0.001 pp | USD5.18 +49.0% | 3 qtrs — |
| 59 | BURKEHILL GLOBAL MANAGEMENT, LP | 125.0K +125.0K (+100.0%) | 965.0K +965.0K (+100.0%) | 0.17% +0.171 pp | 0.06% +0.064 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 60 | BANK OF NEW YORK MELLON CORP | 122.7K +8.4K (+7.3%) | 947.2K -62.3K (-6.2%) | 0.17% -0.005 pp | 0.00% +0.000 pp | USD4.21 +83.4% | 11 qtrs — |
| 61 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 104.9K +69.0K (+192.3%) | 810.2K +493.2K (+155.6%) | 0.14% +0.089 pp | 0.01% +0.003 pp | USD8.10 -4.7% | 2 qtrs — |
| 62 | INVESCO LTD. | 104.1K -46.4K (-30.8%) | 803.6K -525.0K (-39.5%) | 0.14% -0.085 pp | 0.00% 0.000 pp | USD7.43 +3.9% | 7 qtrs — |
| 63 | ROYAL BANK OF CANADA | 96.0K -316.5K (-76.7%) | 741.0K -2.9M (-79.7%) | 0.13% -0.492 pp | 0.00% -0.001 pp | USD4.70 +64.3% | 11 qtrs — |
| 64 | JANUS HENDERSON GROUP PLC | 88.9K +88.9K (+100.0%) | 685.9K +685.9K (+100.0%) | 0.12% +0.122 pp | 0.00% +0.000 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 65 | PRELUDE CAPITAL MANAGEMENT, LLC | 74.2K +74.2K (+100.0%) | 573.0K +573.0K (+100.0%) | 0.10% +0.102 pp | 0.04% +0.042 pp | USD7.72 +0.0% | 3 qtrs — |
| 66 | CAPTION MANAGEMENT, LLC | 70.4K +70.4K (+100.0%) | 543.5K +543.5K (+100.0%) | 0.10% +0.096 pp | 0.00% +0.004 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 67 | BOOTHBAY FUND MANAGEMENT, LLC | 68.5K +68.5K (+100.0%) | 529.1K +529.1K (+100.0%) | 0.09% +0.094 pp | 0.01% +0.008 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 68 | ALLIANCEBERNSTEIN L.P. | 67.3K +— (+0.0%) | 519.3K -74.7K (-12.6%) | 0.09% -0.010 pp | 0.00% +0.000 pp | USD4.01 +92.5% | 7 qtrs — |
| 69 | WELLS FARGO & COMPANY/MN | 62.6K +28.1K (+81.6%) | 483.2K +178.9K (+58.8%) | 0.09% +0.034 pp | 0.00% +0.000 pp | USD6.72 +14.9% | 11 qtrs — |
| 70 | RHUMBLINE ADVISERS | 60.5K +2.5K (+4.3%) | 467.1K -45.0K (-8.8%) | 0.08% -0.005 pp | 0.00% +0.000 pp | USD4.49 +71.9% | 11 qtrs — |
| 71 | FOX RUN MANAGEMENT, L.L.C. | 57.1K +57.1K (+100.0%) | 441.1K +441.1K (+100.0%) | 0.08% +0.078 pp | 0.07% +0.068 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 72 | AQR CAPITAL MANAGEMENT LLC | 49.0K -8.3K (-14.5%) | 378.3K -127.8K (-25.2%) | 0.07% -0.020 pp | 0.00% 0.000 pp | USD5.60 +37.9% | 6 qtrs — |
| 73 | PROFUND ADVISORS LLC | 47.7K +27.9K (+141.0%) | 368.0K +193.3K (+110.7%) | 0.07% +0.035 pp | 0.01% +0.006 pp | USD6.24 +23.7% | 3 qtrs — |
| 74 | DEUTSCHE BANK AG\ | 45.6K +7.2K (+18.8%) | 351.8K +13.1K (+3.9%) | 0.06% +0.004 pp | 0.00% +0.000 pp | USD5.41 +42.7% | 7 qtrs — |
| 75 | CETERA INVESTMENT ADVISERS | 43.4K +43.4K (+100.0%) | 334.9K +334.9K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 76 | ENVESTNET ASSET MANAGEMENT INC | 42.5K +42.5K (+100.0%) | 327.9K +327.9K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.000 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 77 | CANTOR FITZGERALD, L. P. | 42.3K +42.3K (+100.0%) | 326.2K +326.2K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.005 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 78 | STIFEL FINANCIAL CORP | 39.8K -2.3K (-5.5%) | 307.0K -64.7K (-17.4%) | 0.05% -0.009 pp | 0.00% 0.000 pp | USD5.57 +38.6% | 11 qtrs — |
| 79 | STATE OF WISCONSIN INVESTMENT BOARD | 39.1K +39.1K (+100.0%) | 301.9K +301.9K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.001 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 80 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 32.4K +6.8K (+26.6%) | 248.4K +23.6K (+10.5%) | 0.04% +0.006 pp | 0.00% +0.000 pp | USD4.74 +62.9% | 6 qtrs — |
| 81 | AQUATIC CAPITAL MANAGEMENT LLC | 30.9K +30.9K (+100.0%) | 238.8K +238.8K (+100.0%) | 0.04% +0.042 pp | 0.01% +0.007 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 82 | METLIFE INVESTMENT MANAGEMENT, LLC | 28.9K +2.8K (+10.6%) | 223.3K -7.5K (-3.3%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD5.27 +46.5% | 5 qtrs — |
| 83 | VIRTUS INVESTMENT ADVISERS, INC. | 27.7K +27.7K (+100.0%) | 213.7K +213.7K (+100.0%) | 0.04% +0.038 pp | 0.06% +0.058 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 84 | PRICE T ROWE ASSOCIATES INC /MD/ | 27.2K -550.8K (-95.3%) | 211.0K -4.9M (-95.9%) | 0.04% -0.837 pp | 0.00% -0.001 pp | USD8.62 -10.4% | 6 qtrs — |
| 85 | QUARRY LP | 27.0K +27.0K (+100.0%) | 208.4K +208.4K (+100.0%) | 0.04% +0.037 pp | 0.03% +0.033 pp | USD7.72 +0.0% | 1 qtrs NEW |
| 86 | ARIES WEALTH MANAGEMENT | 26.2K +— (+0.0%) | 202.6K -29.1K (-12.6%) | 0.04% -0.004 pp | 0.04% -0.010 pp | USD6.22 +24.1% | 10 qtrs — |
| 87 | NEWEDGE WEALTH, LLC | 25.9K +— (+0.0%) | 199.8K -11.4K (-5.4%) | 0.04% -0.004 pp | 0.00% -0.001 pp | USD7.44 +3.8% | 11 qtrs — |
| 88 | JANE STREET GROUP, LLC | 25.6K +700.0 (+2.8%) | 197.6K -22.2K (-10.1%) | 0.04% -0.003 pp | 0.00% +0.000 pp | USD4.25 +81.6% | 3 qtrs — |
| 89 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 25.2K +25.2K (+100.0%) | 194.3K +194.3K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.002 pp | USD7.72 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
806.00
Cash buys
—
Cash sales
1.00
Net activity
-806
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 806 | 5.82 | 4.7K | 612,113 | D | ↗ |
| 2026-03-20 | Calkins Daniel | Officer | A-Award | D | Common Stock | 57 | 5.74 | 327.18 | 121,327 | D | ↗ |
| 2026-02-04 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 970 | 6.69 | 6.5K | 612,919 | D | ↗ |
| 2026-01-21 | Paterson Dan | Director / Officer | A-Award | A | Common Stock | 213,785 | 0.00 | — | 613,889 | D | ↗ |
| 2026-01-21 | Calkins Daniel | Officer | A-Award | A | Common Stock | 16,665 | 0.00 | — | 121,384 | D | ↗ |
| 2026-01-12 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 10,321 | 7.16 | 73.9K | 400,104 | D | ↗ |
| 2026-01-12 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 5,039 | 7.16 | 36.1K | 104,719 | D | ↗ |
| 2026-01-06 | Kauffman Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 6.88 | 1.38M | 200,000 | D | ↗ |
| 2025-12-24 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 80 | 7.86 | 628.80 | 109,758 | D | ↗ |
| 2025-12-16 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 592 | 9.14 | 5.4K | 101,147 | D | ↗ |
| 2025-12-16 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 393 | 9.14 | 3.6K | 410,425 | D | ↗ |
| 2025-12-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 283 | 9.14 | 2.6K | 41,678 | D | ↗ |
| 2025-12-11 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.00 | 20.0K | 410,818 | D | ↗ |
| 2025-12-10 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.07 | 20.1K | 412,818 | D | ↗ |
| 2025-12-09 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.25 | 20.5K | 414,818 | D | ↗ |
| 2025-12-08 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.50 | 21.0K | 416,818 | D | ↗ |
| 2025-12-05 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.61 | 21.2K | 418,818 | D | ↗ |
| 2025-12-04 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.00 | 20.0K | 420,818 | D | ↗ |
| 2025-12-03 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.00 | 20.0K | 422,818 | D | ↗ |
| 2025-12-02 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.32 | 20.6K | 424,818 | D | ↗ |
| 2025-12-01 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.39 | 20.8K | 426,818 | D | ↗ |
| 2025-11-28 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.79 | 21.6K | 428,818 | D | ↗ |
| 2025-11-26 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.32 | 20.6K | 430,818 | D | ↗ |
| 2025-11-25 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.00 | 20.0K | 432,818 | D | ↗ |
| 2025-11-24 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.00 | 20.0K | 434,818 | D | ↗ |
| 2025-11-21 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 2,000 | 10.00 | 20.0K | 436,818 | D | ↗ |
| 2025-11-21 | Kauffman Michael | Director | S-Sale | D | Common Stock | 8,550 | 10.00 | 85.5K | 8,666 | D | ↗ |
| 2025-11-21 | Bunn Paul A. | Director | M-Exempt | D | Stock Options (right to buy) | 6,250 | 3.27 | 20.4K | 6,250 | D | ↗ |
| 2025-11-03 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 1,299 | 9.35 | 12.1K | 440,818 | D | ↗ |
| 2025-10-09 | Bunn Paul A. | Director | S-Sale | D | Common Stock | 8,333 | 9.06 | 75.5K | 8,333 | D | ↗ |
| 2025-09-24 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 25 | 9.23 | 230.75 | 109,838 | D | ↗ |
| 2025-09-22 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 57 | 9.08 | 517.56 | 109,863 | D | ↗ |
| 2025-09-16 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 587 | 9.99 | 5.9K | 101,739 | D | ↗ |
| 2025-09-16 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 390 | 9.99 | 3.9K | 442,117 | D | ↗ |
| 2025-09-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 281 | 9.99 | 2.8K | 41,961 | D | ↗ |
| 2025-08-06 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 1,332 | 5.81 | 7.7K | 442,507 | D | ↗ |
| 2025-06-23 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 25 | 4.71 | 117.75 | 109,920 | D | ↗ |
| 2025-06-20 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 17,808 | 5.13 | 91.4K | 443,839 | D | ↗ |
| 2025-06-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 4,110 | 5.13 | 21.1K | 109,945 | D | ↗ |
| 2025-06-16 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 594 | 5.65 | 3.4K | 102,326 | D | ↗ |
| 2025-06-16 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 335 | 5.65 | 1.9K | 461,647 | D | ↗ |
| 2025-06-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 284 | 5.65 | 1.6K | 42,242 | D | ↗ |
| 2025-05-22 | Tollefson Karin Anna | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 16,666 | D | ↗ |
| 2025-05-22 | Stuglik Brian M | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 102,920 | D | ↗ |
| 2025-05-22 | Rowinsky Eric K | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 16,666 | D | ↗ |
| 2025-05-22 | ROBERTSON MICHELLE | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 7.48 | 93.5K | 12,500 | D | ↗ |
| 2025-05-22 | Kauffman Michael | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 7.48 | 93.5K | 12,500 | D | ↗ |
| 2025-05-22 | Kapur Anil | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 7.48 | 93.5K | 12,500 | D | ↗ |
| 2025-05-22 | JOHNSON JOHN | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 16,666 | D | ↗ |
| 2025-05-22 | Gagnon Robert E. | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 7.48 | 93.5K | 12,500 | D | ↗ |
| 2025-05-22 | Bunn Paul A. | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 7.48 | 93.5K | 12,500 | D | ↗ |
| 2025-05-20 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 58,677 | 8.13 | 477.0K | 461,982 | D | ↗ |
| 2025-05-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 11,143 | 8.13 | 90.6K | 114,055 | D | ↗ |
| 2025-05-16 | Paterson Dan | Director / Officer | A-Award | D | Common Stock | 25,000 | 0.00 | — | 370,659 | D | ↗ |
| 2025-05-16 | Calkins Daniel | Officer | A-Award | D | Common Stock | 38,850 | 0.00 | — | 125,198 | D | ↗ |
| 2025-05-05 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 820 | 7.30 | 6.0K | 345,659 | D | ↗ |
| 2025-04-01 | Ros Matthew | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2025-03-24 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 26 | 7.04 | 183.04 | 86,348 | D | ↗ |
| 2025-03-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 65 | 6.89 | 447.85 | 86,374 | D | ↗ |
| 2025-03-17 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 593 | 6.95 | 4.1K | 94,587 | D | ↗ |
| 2025-03-17 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 244 | 6.95 | 1.7K | 346,479 | D | ↗ |
| 2025-03-17 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 284 | 6.95 | 2.0K | 34,193 | D | ↗ |
| 2025-02-04 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 858 | 5.70 | 4.9K | 346,723 | D | ↗ |
| 2025-01-14 | Ros Matthew | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-13 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 8,568 | 5.24 | 44.9K | 347,581 | D | ↗ |
| 2025-01-10 | Paterson Dan | Director / Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 356,149 | D | ↗ |
| 2025-01-10 | Calkins Daniel | Officer | A-Award | A | Common Stock | 38,800 | 0.00 | — | 86,439 | D | ↗ |
| 2025-01-06 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 6 | 6.94 | 41.64 | 47,639 | D | ↗ |
| 2024-12-24 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 28 | 3.91 | 109.48 | 47,368 | D | ↗ |
| 2024-12-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 65 | 4.34 | 282.10 | 47,396 | D | ↗ |
| 2024-12-19 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 334 | 4.37 | 1.5K | 95,180 | D | ↗ |
| 2024-12-19 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 183 | 4.37 | 799.71 | 231,149 | D | ↗ |
| 2024-12-19 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 130 | 4.37 | 568.10 | 34,477 | D | ↗ |
| 2024-12-16 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 595 | 4.54 | 2.7K | 95,514 | D | ↗ |
| 2024-12-16 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 244 | 4.54 | 1.1K | 231,332 | D | ↗ |
| 2024-12-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 285 | 4.54 | 1.3K | 34,607 | D | ↗ |
| 2024-11-05 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 812 | 3.84 | 3.1K | 231,576 | D | ↗ |
| 2024-10-07 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 6 | 2.86 | 17.16 | 47,461 | D | ↗ |
| 2024-09-24 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 28 | 2.68 | 75.04 | 47,467 | D | ↗ |
| 2024-09-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 65 | 2.80 | 182.00 | 47,495 | D | ↗ |
| 2024-09-19 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 336 | 2.79 | 937.44 | 96,109 | D | ↗ |
| 2024-09-19 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 184 | 2.79 | 513.36 | 232,388 | D | ↗ |
| 2024-09-19 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 131 | 2.79 | 365.49 | 34,892 | D | ↗ |
| 2024-09-16 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 600 | 2.80 | 1.7K | 96,445 | — | ↗ |
| 2024-09-16 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 246 | 2.80 | 688.80 | 232,572 | — | ↗ |
| 2024-09-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 287 | 2.80 | 803.60 | 35,023 | — | ↗ |
| 2024-08-05 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 3,245 | 2.16 | 7.0K | 232,818 | — | ↗ |
| 2024-07-09 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 7 | 2.62 | 18.34 | 47,560 | — | ↗ |
| 2024-06-24 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 28 | 3.15 | 88.20 | 47,290 | — | ↗ |
| 2024-06-20 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 335 | 3.21 | 1.1K | 97,045 | — | ↗ |
| 2024-06-20 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 183 | 3.21 | 587.43 | 236,063 | — | ↗ |
| 2024-06-20 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 131 | 3.21 | 420.51 | 35,310 | — | ↗ |
| 2024-06-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 67 | 3.16 | 211.72 | 47,318 | — | ↗ |
| 2024-06-18 | Tollefson Karin Anna | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 8,333 | — | ↗ |
| 2024-06-18 | Stuglik Brian M | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 97,380 | — | ↗ |
| 2024-06-18 | Rowinsky Eric K | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 3.27 | 40.9K | 12,500 | — | ↗ |
| 2024-06-18 | ROBERTSON MICHELLE | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 3.27 | 40.9K | 12,500 | — | ↗ |
| 2024-06-18 | Paterson Dan | Director / Officer | A-Award | A | Common Stock | 150,000 | 0.00 | — | 236,246 | — | ↗ |
| 2024-06-18 | Kauffman Michael | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 8,883 | — | ↗ |
| 2024-06-18 | Kapur Anil | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 3.27 | 40.9K | 12,500 | — | ↗ |
| 2024-06-18 | JOHNSON JOHN | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 8,333 | — | ↗ |
| 2024-06-18 | Gagnon Robert E. | Director | A-Award | A | Common Stock | 8,333 | 0.00 | — | 35,441 | — | ↗ |
| 2024-06-18 | Calkins Daniel | Officer | A-Award | A | Common Stock | 38,850 | 0.00 | — | 47,385 | — | ↗ |
| 2024-06-18 | Bunn Paul A. | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 3.27 | 40.9K | 12,500 | — | ↗ |
| 2024-06-17 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 593 | 3.49 | 2.1K | 89,047 | — | ↗ |
| 2024-06-17 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 244 | 3.49 | 851.56 | 86,246 | — | ↗ |
| 2024-06-17 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 283 | 3.49 | 987.67 | 27,108 | — | ↗ |
| 2024-04-05 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 6 | 10.87 | 65.22 | 8,535 | — | ↗ |
| 2024-03-25 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 25 | 12.02 | 300.50 | 8,541 | — | ↗ |
| 2024-03-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 55 | 11.07 | 608.85 | 8,566 | — | ↗ |
| 2024-03-19 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 273 | 10.38 | 2.8K | 89,640 | — | ↗ |
| 2024-03-19 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 182 | 10.38 | 1.9K | 86,490 | — | ↗ |
| 2024-03-19 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 130 | 10.38 | 1.3K | 27,391 | — | ↗ |
| 2024-03-18 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 537 | 10.71 | 5.8K | 89,913 | — | ↗ |
| 2024-03-18 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 244 | 10.71 | 2.6K | 86,672 | — | ↗ |
| 2024-03-18 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 283 | 10.71 | 3.0K | 27,521 | — | ↗ |
| 2024-03-11 | Stuglik Brian M | Director | A-Award | A | Stock Option (right to buy) | 11,865 | 11.44 | 135.7K | 11,865 | — | ↗ |
| 2024-03-11 | Rowinsky Eric K | Director | A-Award | A | Stock Option (right to buy) | 12,572 | 11.44 | 143.8K | 12,572 | — | ↗ |
| 2024-03-11 | ROBERTSON MICHELLE | Director | D-Return | D | Stock Option (right to buy) | 5,291 | 37.32 | 197.5K | 0 | — | ↗ |
| 2024-03-11 | Paterson Dan | Director / Officer | D-Return | D | Stock Option (right to buy) | 12,064 | 110.28 | 1.33M | 0 | — | ↗ |
| 2024-03-11 | Kauffman Michael | Director | A-Award | A | Stock Option (right to buy) | 16,078 | 11.44 | 183.9K | 16,078 | — | ↗ |
| 2024-03-11 | JOHNSON JOHN | Director | A-Award | A | Stock Option (right to buy) | 8,549 | 11.44 | 97.8K | 8,549 | — | ↗ |
| 2024-03-11 | Calkins Daniel | Officer | D-Return | D | Stock Option (right to buy) | 1,875 | 27.72 | 52.0K | 0 | — | ↗ |
| 2024-03-11 | Bunn Paul A. | Director | A-Award | A | Stock Option (right to buy) | 6,113 | 11.44 | 69.9K | 6,113 | — | ↗ |
| 2024-02-06 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 9,204 | 13.70 | 126.1K | 27,804 | — | ↗ |
| 2024-01-12 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 9,204 | 10.95 | 100.8K | 37,008 | — | ↗ |
| 2024-01-05 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 6 | 8.50 | 51.00 | 8,621 | — | ↗ |
| 2023-12-26 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 25 | 8.08 | 202.00 | 8,350 | — | ↗ |
| 2023-12-20 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 57 | 7.93 | 452.01 | 8,375 | — | ↗ |
| 2023-12-19 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 274 | 7.73 | 2.1K | 90,450 | — | ↗ |
| 2023-12-19 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 183 | 7.73 | 1.4K | 86,916 | — | ↗ |
| 2023-12-19 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 130 | 7.73 | 1.0K | 46,212 | — | ↗ |
| 2023-12-18 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 487 | 7.64 | 3.7K | 90,724 | — | ↗ |
| 2023-12-18 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 244 | 7.64 | 1.9K | 87,099 | — | ↗ |
| 2023-12-18 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 284 | 7.64 | 2.2K | 46,342 | — | ↗ |
| 2023-10-24 | Calkins Daniel | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 6.89 | 172.3K | 25,000 | — | ↗ |
| 2023-10-05 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 5 | 7.30 | 36.50 | 8,432 | — | ↗ |
| 2023-09-25 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 25 | 9.40 | 235.00 | 8,437 | — | ↗ |
| 2023-09-21 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 232 | 9.31 | 2.2K | 8,462 | — | ↗ |
| 2023-09-19 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 274 | 9.84 | 2.7K | 91,211 | — | ↗ |
| 2023-09-19 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 183 | 9.84 | 1.8K | 87,343 | — | ↗ |
| 2023-09-19 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 130 | 9.84 | 1.3K | 46,626 | — | ↗ |
| 2023-09-18 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 478 | 9.91 | 4.7K | 91,485 | — | ↗ |
| 2023-09-18 | Paterson Dan | Director / Officer | S-Sale | D | Common Stock | 240 | 9.91 | 2.4K | 87,526 | — | ↗ |
| 2023-09-18 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 278 | 9.91 | 2.8K | 46,756 | — | ↗ |
| 2023-08-02 | Paterson Dan | Director / Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 87,766 | — | ↗ |
| 2023-07-06 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 5 | 8.02 | 40.10 | 8,694 | — | ↗ |
| 2023-06-26 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 26 | 8.17 | 212.42 | 8,422 | — | ↗ |
| 2023-06-20 | Stuglik Brian M | Director / Officer | S-Sale | D | Common Stock | 275 | 10.30 | 2.8K | 91,963 | — | ↗ |
| 2023-06-20 | Paterson Dan | Officer | S-Sale | D | Common Stock | 183 | 10.30 | 1.9K | 37,766 | — | ↗ |
| 2023-06-20 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 130 | 10.30 | 1.3K | 47,034 | — | ↗ |
| 2023-06-16 | Stuglik Brian M | Director / Officer | S-Sale | D | Common Stock | 487 | 9.92 | 4.8K | 92,238 | — | ↗ |
| 2023-06-16 | Paterson Dan | Officer | S-Sale | D | Common Stock | 244 | 9.92 | 2.4K | 37,949 | — | ↗ |
| 2023-06-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 283 | 9.92 | 2.8K | 47,164 | — | ↗ |
| 2023-05-15 | Tollefson Karin Anna | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-15 | Rowinsky Eric K | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.42 | 26.3K | 62,500 | — | ↗ |
| 2023-05-15 | ROBERTSON MICHELLE | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.42 | 26.3K | 62,500 | — | ↗ |
| 2023-05-15 | Kauffman Michael | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.42 | 26.3K | 62,500 | — | ↗ |
| 2023-05-15 | Kapur Anil | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.42 | 26.3K | 62,500 | — | ↗ |
| 2023-05-15 | JOHNSON JOHN | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.42 | 26.3K | 62,500 | — | ↗ |
| 2023-05-15 | Gagnon Robert E. | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.42 | 26.3K | 62,500 | — | ↗ |
| 2023-05-15 | Bunn Paul A. | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.42 | 26.3K | 62,500 | — | ↗ |
| 2023-04-05 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 75 | 0.37 | 27.75 | 101,397 | — | ↗ |
| 2023-03-24 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 378 | 0.42 | 158.76 | 101,472 | — | ↗ |
| 2023-03-20 | Stuglik Brian M | Director / Officer | S-Sale | D | Common Stock | 3,508 | 0.43 | 1.5K | 1,112,736 | — | ↗ |
| 2023-03-20 | Paterson Dan | Officer | S-Sale | D | Common Stock | 2,339 | 0.43 | 1.0K | 458,351 | — | ↗ |
| 2023-03-20 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 1,664 | 0.43 | 715.52 | 569,399 | — | ↗ |
| 2023-03-16 | Stuglik Brian M | Director / Officer | S-Sale | D | Common Stock | 6,276 | 0.40 | 2.5K | 1,116,244 | — | ↗ |
| 2023-03-16 | Paterson Dan | Officer | S-Sale | D | Common Stock | 3,138 | 0.40 | 1.3K | 460,690 | — | ↗ |
| 2023-03-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 3,654 | 0.40 | 1.5K | 571,063 | — | ↗ |
| 2023-01-27 | Stuglik Brian M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,216,355 | 0.66 | 1.46M | 2,216,355 | — | ↗ |
| 2023-01-27 | Paterson Dan | Officer | A-Award | A | Stock Option (Right to Buy) | 1,680,880 | 0.66 | 1.11M | 1,680,880 | — | ↗ |
| 2023-01-27 | Calkins Daniel | Officer | A-Award | A | Stock Option (Right to Buy) | 165,000 | 0.66 | 108.9K | 165,000 | — | ↗ |
| 2023-01-05 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 74 | 0.43 | 31.82 | 98,517 | — | ↗ |
| 2022-12-27 | Calkins Daniel | Officer | S-Sale | D | Common Stock | 1,246 | 0.33 | 411.18 | 98,591 | — | ↗ |
| 2022-12-19 | Stuglik Brian M | Officer | S-Sale | D | Common Stock | 3,556 | 0.37 | 1.3K | 1,122,520 | — | ↗ |
| 2022-12-19 | Paterson Dan | Officer | S-Sale | D | Common Stock | 2,954 | 0.37 | 1.1K | 463,828 | — | ↗ |
| 2022-12-19 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 1,429 | 0.37 | 528.73 | 574,717 | — | ↗ |
| 2022-12-16 | Stuglik Brian M | Officer | S-Sale | D | Common Stock | 25,162 | 0.40 | 10.1K | 1,126,076 | — | ↗ |
| 2022-12-16 | Paterson Dan | Officer | S-Sale | D | Common Stock | 15,676 | 0.40 | 6.3K | 466,782 | — | ↗ |
| 2022-12-16 | Gagnon Robert E. | Director | S-Sale | D | Common Stock | 12,408 | 0.40 | 5.0K | 576,146 | — | ↗ |
| 2022-12-13 | Gagnon Robert E. | Director | — | D | Stock Option (right to buy) | 301,500 | 2.36 | 711.5K | — | — | ↗ |
| 2022-10-31 | Calkins Daniel | Officer | — | D | Stock Option (right to buy) | 52,500 | 0.87 | 45.7K | — | — | ↗ |
| 2022-10-20 | Kapur Anil | Director | A-Award | A | Stock Option (right to buy) | 163,185 | 0.00 | — | 163,185 | — | ↗ |
| 2022-09-19 | Stuglik Brian M | Director / Officer | S-Sale | D | Common Stock | 3,355 | 1.13 | 3.8K | 1,151,238 | — | ↗ |
| 2022-09-19 | Gagnon Robert E. | Officer | S-Sale | D | Common Stock | 1,348 | 1.13 | 1.5K | 588,554 | — | ↗ |
| 2022-08-01 | Stuglik Brian M | Officer | S-Sale | D | Common Stock | 5,858 | 1.08 | 6.3K | 1,154,593 | — | ↗ |
| 2022-06-22 | Solomon Lesley Kim | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.00 | — | 62,500 | — | ↗ |
| 2022-06-22 | Rowinsky Eric K | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 1.11 | 69.4K | 62,500 | — | ↗ |
| 2022-06-22 | ROBERTSON MICHELLE | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.00 | — | 62,500 | — | ↗ |
| 2022-06-22 | Kauffman Michael | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.00 | — | 62,500 | — | ↗ |
| 2022-06-22 | JOHNSON JOHN | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.00 | — | 62,500 | — | ↗ |
| 2022-06-22 | Bunn Paul A. | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.00 | — | 62,500 | — | ↗ |
| 2022-06-21 | Stuglik Brian M | Officer | S-Sale | D | Common Stock | 3,362 | 1.14 | 3.8K | 1,160,451 | — | ↗ |
| 2022-06-21 | Paterson Dan | Officer | S-Sale | D | Common Stock | 2,701 | 1.14 | 3.1K | 485,244 | — | ↗ |
| 2022-06-21 | Gagnon Robert E. | Officer | S-Sale | D | Common Stock | 1,351 | 1.14 | 1.5K | 589,902 | — | ↗ |
| 2022-05-14 | Stuglik Brian M | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 1,177,607 | — | ↗ |
| 2022-05-14 | Paterson Dan | Officer | S-Sale | D | Common Stock | 4,988 | 1.03 | 5.1K | 487,945 | — | ↗ |
| 2022-05-14 | Gagnon Robert E. | Officer | S-Sale | D | Common Stock | 16,627 | 1.03 | 17.1K | 591,253 | — | ↗ |
| 2022-05-12 | Solomon Lesley Kim | Director | A-Award | A | Stock Option (right to buy) | 62,500 | 0.00 | — | 62,500 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-21.8K
Shares Outstanding
69.31M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Daniel Paterson President and Chief Executive Officer | 674.0K | — | 1.16M | — | 489.3K | 25.0K | 2.35M | 49.43% | ↗ |
| 2 | 2025 | Matthew Ros Former Chief Operating Officer | 455.2K | — | 585.3K | — | 196.4K | 388.3K | 1.63M | 36.02% | ↗ |
| 3 | 2025 | Daniel Calkins Chief Financial Officer | 350.0K | — | 450.7K | — | 151.2K | 25.0K | 976.9K | 46.14% | ↗ |
| 4 | 2025 | Michael Kauffman, M.D., Ph.D. President of Development | 30.0K | — | 62.3K | 75.7K | — | 105.0K | 273.0K | 50.55% | ↗ |
| 5 | 2024 | Daniel Paterson President and Chief Executive Officer | 648.0K | — | 981.0K | 527.9K | 356.0K | 23.9K | 2.54M | 59.48% | ↗ |
| 6 | 2024 | Daniel Calkins Chief Financial Officer | 325.0K | — | 254.1K | 15.2K | 124.0K | 22.7K | 741.0K | 36.34% | ↗ |
| 7 | 2023 | Daniel Paterson President and Chief Executive Officer | 544.8K | — | 1.04M | 1.69M | 330.0K | 22.8K | 3.63M | 75.25% | ↗ |
| 8 | 2023 | Brian M. Stuglik Former Chief Executive Officer | 389.4K | — | — | 1.13M | 421.9K | 83.4K | 2.02M | 55.74% | ↗ |
| 9 | 2023 | Daniel Calkins Chief Financial Officer | 257.5K | — | — | 220.7K | 126.0K | 18.3K | 622.6K | 35.46% | ↗ |
| 10 | 2022 | Brian M. Stuglik Former Chief Executive Officer | 624.0K | — | — | — | 356.7K | 49.3K | 1.03M | 0.00% | ↗ |
| 11 | 2022 | Brian M. Stuglik Chief Executive Officer | 624.0K | — | — | — | 356.7K | 49.3K | 1.03M | 0.00% | ↗ |
| 12 | 2022 | Daniel Paterson President and Chief Executive Officer | 470.0K | — | — | — | 206.7K | 21.3K | 698.0K | 0.00% | ↗ |
| 13 | 2022 | Daniel Paterson President and Chief Operating Officer | 470.0K | — | — | — | 206.7K | 21.3K | 698.0K | 0.00% | ↗ |
| 14 | 2022 | Daniel Paterson President and Chief Executive Officer and Former Chief Operating Officer | 470.0K | — | — | — | 206.7K | 21.3K | 698.0K | 0.00% | ↗ |
| 15 | 2022 | Robert Gagnon Former Chief Business and Financial Officer | 368.1K | — | — | — | — | 21.2K | 389.3K | 0.00% | ↗ |
| 16 | 2022 | Daniel Calkins Vice President, Finance | 221.7K | — | 30.6K | 34.3K | 72.9K | 16.0K | 375.5K | 17.28% | ↗ |
| 17 | 2022 | Daniel Calkins Chief Financial Officer and Former Vice President of Finance | 221.7K | — | 30.6K | 34.3K | 72.9K | 16.0K | 375.5K | 17.28% | ↗ |
| 18 | 2022 | Daniel Calkins Chief Financial Officer | 221.7K | — | 30.6K | 34.3K | 72.9K | 16.0K | 375.5K | 17.28% | ↗ |
| 19 | 2021 | Brian M. Stuglik Chief Executive Officer | 600.0K | — | 1.53M | 1.25M | 390.0K | 48.4K | 3.82M | 72.78% | ↗ |
| 20 | 2021 | Brian M. Stuglik Former Chief Executive Officer | 600.0K | — | 1.53M | 1.25M | 390.0K | 48.4K | 3.82M | 72.78% | ↗ |
| 21 | 2021 | Daniel Paterson President and Chief Executive Officer and Former Chief Operating Officer | 460.0K | — | 494.8K | 628.5K | 230.0K | 20.4K | 1.83M | 61.26% | ↗ |
| 22 | 2021 | Daniel Paterson President and Chief Operating Officer | 460.0K | — | 494.8K | 628.5K | 230.0K | 20.4K | 1.83M | 61.26% | ↗ |
| 23 | 2021 | Robert Gagnon Chief Business and Financial Officer | 415.0K | — | 572.0K | 515.6K | 174.0K | 20.4K | 1.70M | 64.09% | ↗ |
| 24 | 2021 | Robert Gagnon Former Chief Business and Financial Officer | 415.0K | — | 572.0K | 515.6K | 174.0K | 20.4K | 1.70M | 64.09% | ↗ |
| 25 | 2020 | Brian M. Stuglik Chief Executive Officer | 609.2K | — | 1.27M | 1.04M | 507.0K | 42.4K | 3.47M | 66.64% | ↗ |
| 26 | 2020 | Daniel Paterson President and Chief Operating Officer | 467.1K | — | 928.8K | 693.1K | 299.0K | 14.0K | 2.40M | 67.52% | ↗ |
| 27 | 2020 | Robert Gagnon Chief Business and Financial Officer | 421.4K | — | 706.5K | 347.1K | 215.8K | 14.0K | 1.70M | 61.80% | ↗ |
| 28 | 2019 | Brian M. Stuglik Chief Executive Officer | 253.8K | — | 386.1K | 943.6K | 200.0K | 133.6K | 1.92M | 69.36% | ↗ |
| 29 | 2019 | Robert Forrester Former Chief Executive Officer | 309.8K | — | — | 1.24M | — | 305.8K | 1.86M | 66.89% | ↗ |
| 30 | 2019 | Daniel Paterson President and Chief Operating Officer | 445.3K | — | — | 1.06M | 230.0K | 4.6K | 1.74M | 60.84% | ↗ |
| 31 | 2019 | Robert Gagnon Chief Business and Financial Officer | 396.4K | — | 181.0K | 829.7K | 176.0K | 14.3K | 1.60M | 63.27% | ↗ |
| 32 | 2018 | Robert Gagnon Chief Financial Officer | 115.5K | 40.0K | 471.5K | 2.35M | 63.3K | 6.7K | 3.04M | 92.59% | ↗ |
| 33 | 2018 | Robert Gagnon Chief Business and Financial Officer | 115.5K | 40.0K | 471.5K | 2.35M | 63.3K | 6.7K | 3.04M | 92.59% | ↗ |
| 34 | 2018 | Robert Forrester Former Chief Executive Officer | 554.2K | — | — | 498.4K | 545.0K | 15.0K | 1.61M | 30.91% | ↗ |
| 35 | 2018 | Robert Forrester Chief Executive Officer | 554.2K | — | — | 498.4K | 545.0K | 15.0K | 1.61M | 30.91% | ↗ |
| 36 | 2018 | Joseph Lobacki Chief Commercial Officer | 381.5K | 60.0K | — | 878.1K | 200.0K | 12.0K | 1.53M | 57.33% | ↗ |
| 37 | 2017 | Diep Le, M.D. Ph.D. Former Chief Medical Officer | 76.9K | 95.0K | — | 1.13M | 40.0K | 3.4K | 1.34M | 83.95% | ↗ |
| 38 | 2017 | Diep Le, M.D. Ph.D. Chief Medical Officer | 76.9K | 95.0K | — | 1.13M | 40.0K | 3.4K | 1.34M | 83.95% | ↗ |
| 39 | 2017 | Robert Forrester Chief Executive Officer | 535.0K | — | — | 294.8K | 321.0K | 15.0K | 1.17M | 25.29% | ↗ |
| 40 | 2017 | Julie B. Feder Chief Financial Officer | 150.4K | — | — | 878.0K | 60.0K | 6.7K | 1.10M | 80.18% | ↗ |
| 41 | 2017 | Julie B. Feder Former Chief Financial Officer | 150.4K | — | — | 878.0K | 60.0K | 6.7K | 1.10M | 80.18% | ↗ |
| 42 | 2016 | Robert Forrester Chief Executive Officer | 525.0K | — | — | 245.8K | 321.0K | 12.7K | 1.10M | 22.26% | ↗ |
| 43 | 2016 | Gregory Berk, M.D. Chief Medical Officer | 270.8K | — | — | 452.5K | 106.7K | 187.9K | 1.02M | 44.46% | ↗ |
| 44 | 2016 | Daniel Paterson Chief Operating Officer | 377.0K | — | — | 167.4K | 151.0K | 13.3K | 708.7K | 23.62% | ↗ |
| 45 | 2015 | Robert Forrester Chief Executive Officer | 524.4K | — | — | 1.97M | — | 12.5K | 2.51M | 78.61% | ↗ |
| 46 | 2015 | Daniel Paterson Chief Operating Officer | 376.2K | — | — | 1.04M | — | 12.5K | 1.43M | 72.85% | ↗ |
| 47 | 2015 | Joanna Horobin former Chief Medical Officer | 210.5K | — | — | 591.7K | — | 331.0K | 1.13M | 52.22% | ↗ |
| 48 | 2015 | John Green Chief Financial Officer | 337.8K | — | — | 330.3K | — | 13.4K | 681.5K | 48.47% | ↗ |
| 49 | 2014 | Robert Forrester Chief Executive Officer | 504.6K | — | — | 4.74M | 303.0K | 16.9K | 5.56M | 85.18% | ↗ |
| 50 | 2014 | Robert Forrester Chief Executive Officer | 504.6K | — | — | 4.74M | 303.0K | 12.5K | 5.56M | 85.25% | ↗ |
| 51 | 2014 | Daniel Paterson Chief Operating Officer | 363.1K | — | — | 1.90M | 140.0K | 12.5K | 2.41M | 78.62% | ↗ |
| 52 | 2014 | Daniel Paterson Chief Operating Officer | 363.1K | — | — | 1.90M | 140.0K | 12.5K | 2.41M | 78.62% | ↗ |
| 53 | 2014 | Joanna Horobin Chief Medical Officer | 388.9K | — | — | 947.8K | 136.5K | 15.2K | 1.49M | 63.68% | ↗ |
| 54 | 2014 | Joanna Horobin former Chief Medical Officer | 388.9K | — | — | 947.8K | 136.5K | 13.8K | 1.49M | 63.74% | ↗ |
| 55 | 2014 | John Green Chief Financial Officer | 329.5K | — | — | 568.7K | 85.8K | 13.8K | 997.7K | 57.00% | ↗ |
| 56 | 2013 | Robert Forrester President, Chief Executive | 443.8K | — | — | 2.07M | 248.1K | 15.5K | 2.78M | 74.55% | ↗ |
| 57 | 2013 | Robert Forrester Chief Executive Officer | 443.8K | — | — | 2.07M | 248.1K | 15.5K | 2.78M | 74.55% | ↗ |
| 58 | 2013 | Daniel Paterson Chief Operating Officer | 314.7K | — | — | 513.0K | 150.4K | 12.5K | 990.6K | 51.79% | ↗ |
| 59 | 2013 | Daniel Paterson Chief Business Officer | 314.7K | — | — | 513.0K | 150.4K | 12.5K | 990.6K | 51.79% | ↗ |
| 60 | 2013 | Joanna Horobin Chief Medical Officer | 350.0K | — | — | — | 169.1K | 13.6K | 532.7K | 0.00% | ↗ |
| 61 | 2013 | Christoph Westphal, M.D., Ph.D. Executive Chairman | — | — | — | — | — | — | — | — | ↗ |
| 62 | 2012 | Christoph Westphal, M.D., Ph.D. Chief Executive Officer | — | — | 4.02M | 3.00M | — | — | 7.02M | 100.00% | ↗ |
| 63 | 2012 | Christoph Westphal, M.D., Ph.D. Executive Chairman | — | — | 3.00M | 4.02M | — | — | 7.02M | 100.00% | ↗ |
| 64 | 2012 | Robert Forrester President, Chief Operating Officer | 364.4K | — | 1.57M | — | 190.0K | 14.1K | 2.14M | 73.43% | ↗ |
| 65 | 2012 | Robert Forrester President, Chief Executive | 364.4K | — | 1.57M | — | 190.0K | 14.1K | 2.14M | 73.43% | ↗ |
| 66 | 2012 | Daniel Paterson Chief Business Officer | 244.6K | — | 1.26M | — | 116.0K | 10.3K | 1.63M | 77.22% | ↗ |
| 67 | 2012 | Daniel Paterson Vice President, Head of Corporate Development and Diagnostics | 244.6K | — | 1.26M | — | 116.0K | 10.3K | 1.63M | 77.22% | ↗ |
| 68 | 2012 | Joanna Horobin Chief Medical Officer | 59.2K | — | — | 1.25M | 20.0K | 322.00 | 1.33M | 94.04% | ↗ |
| 69 | 2011 | Robert Forrester President, Chief Operating Officer | 252.8K | — | 35.8K | — | 130.0K | 7.1K | 425.7K | 8.42% | ↗ |
| 70 | 2011 | Daniel Paterson Vice President, Head of Corporate Development and Diagnostics | — | — | — | — | — | — | — | — | ↗ |
| 71 | 2011 | Christoph Westphal, M.D., Ph.D. Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-04-09 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel W. Paterson | President, Chief Executive Officer & Director | 1M | male |
| Michael Glen Kauffman | President of Development & Director | 930.0K | — |
| Daniel Calkins | Chief Financial Officer | 526.2K | male |
| Jonathan Pachter | Chief Scientific Officer | 238.2K | — |
| Nathan Sanburn | Chief Business Officer | — | male |
| Cathy Carew | Chief Organizational Effectiveness Officer | — | female |
| Robert A. Weinberg | Co-Founder & Chair of Scientific Advisory Board | — | — |
| Julissa Viana | Vice President of Corporate Communications & Investor Relations | — | female |
| Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer | — | male |
| Michelle Detwiler | Co-Founder | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VSTM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
